# Single Agent Lenalidomide in Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

> **NCT01401322** · PHASE2 · TERMINATED · sponsor: **Stanford University** · enrollment: 5 (actual)

## Conditions studied

- Leukemia
- Relapsed Adult Acute Lymphocytic Leukemia

## Interventions

- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT01401322
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-01
- **Primary completion:** 2012-01
- **Final completion:** 2012-05
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** low accrual
- **Last updated:** 2016-11-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01401322

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01401322, "Single Agent Lenalidomide in Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01401322. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*